OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC - Govindan, R; Fakih, M; Price, T (Journal of Thoracic Oncology, 2019)
et al.